dichlororibofuranosylbenzimidazole and tamoxifen

dichlororibofuranosylbenzimidazole has been researched along with tamoxifen in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gritsch, D; Komina, O; Maurer, M; Węsierska-Gądek, J; Zulehner, N	1

Other Studies

1 other study(ies) available for dichlororibofuranosylbenzimidazole and tamoxifen

Article	Year
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells. Journal of cellular biochemistry, 2011, Volume: 112, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Purines; RNA Polymerase II; Roscovitine; Tamoxifen; Tumor Suppressor Protein p53	2011

Article

Year

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.

Journal of cellular biochemistry, 2011, Volume: 112, Issue:3

Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Purines; RNA Polymerase II; Roscovitine; Tamoxifen; Tumor Suppressor Protein p53

2011